BlueCross BlueShield of Tennessee Medical Policy Manual

Bevacizumab Products (Avastin®; Mvasi® ; Zirabev™; Alymsys®; Vegzelma™)

Some agents on this policy may require step therapy See “Step Therapy Requirements for Provider Administered Specialty Medications” Document at: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

          I.    INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A.    FDA-Approved Indications

1.     Metastatic Colorectal Cancer (mCRC)

a.     Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer.

b.     Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab product-containing regimen.

2.     First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer.

3.     Recurrent Glioblastoma (RGM)

Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, is indicated for the treatment of recurrent glioblastoma in adults.

4.     Metastatic Renal Cell Carcinoma (mRCC)

Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma.

5.     Persistent, Recurrent, or Metastatic Cervical Cancer

Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

6.     Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

a.     Avastin, Mvasi, Vegzelma or Zirabev, in combination with carboplatin and paclitaxel, followed by Avastin, Mvasi, Vegzelma or Zirabev as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.

b.     Avastin, Alymsys, Mvasi, Vegzelma or Zirabev, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.

c.     Avastin, Mvasi, Vegzelma or Zirabev, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin, Mvasi, Vegzelma or Zirabev as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

7.     Hepatocellular Carcinoma

Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

B.    Compendial Uses

1.     Breast Cancer

2.     Central Nervous System (CNS) Cancers

a.     Glioma (WHO Grade 1)

b.     Diffuse high grade gliomas

c.     Glioblastoma

d.     IDH mutant astrocytoma (WHO Grade 2, 3, or 4)

e.     Oligodendroglioma (WHO Grade 2 or 3)

f.      Intracranial and Spinal Ependymoma (excluding subependymoma)

g.     Medulloblastoma

h.     Primary Central Nervous System Lymphoma

i.      Meningiomas

j.      Limited and Extensive Brain Metastases

k.     Metastatic Spine Tumors

3.     Malignant Pleural Mesothelioma, Malignant Peritoneal Mesothelioma, Pericardial Mesothelioma, Tunica Vaginalis Testis Mesothelioma

4.     Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

5.     Soft Tissue Sarcoma

a.     Angiosarcoma

b.     Solitary Fibrous Tumor/Hemangiopericytoma

6.     Uterine Neoplasms/Endometrial Carcinoma

7.     Vulvar Carcinoma

8.     Small Bowel Adenocarcinoma

9.     Ampullary Adenocarcinoma

10.  Appendiceal Adenocarcinoma

11.  Anal Adenocarcinoma

12.  Renal Cell Carcinoma

13.  Ophthalmic Disorders

a.     Diabetic Macular Edema

b.     Neovascular (wet) Age-Related Macular Degeneration (AMD)

c.     Macular Edema following Retinal Vein Occlusion (RVO)

d.     Proliferative Diabetic Retinopathy

e.     Choroidal Neovascularization (CNV)

f.      Neovascular Glaucoma; adjunct

g.     Retinopathy of Prematurity

h.     Polypoidal Choroidal Vasculopathy

All other indications are considered experimental/investigational and not medically necessary.

         II.    CRITERIA FOR INITIAL APPROVAL

A.    Ophthalmic Disorders

Authorization of 6 months may be granted for treatment of the following retinal disorders:

1.     Diabetic Macular Edema

2.     Neovascular (wet) Age-Related Macular Degeneration

3.     Macular Edema following Retinal Vein Occlusion

4.     Proliferative Diabetic Retinopathy

5.     Choroidal Neovascularization (including myopic choroidal neovascularization, angioid streaks, choroiditis [including choroiditis secondary to ocular histoplasmosis], idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma)

6.     Neovascular Glaucoma

7.     Retinopathy of Prematurity

8.     Polypoidal Choroidal Vasculopathy

B.    Colorectal Cancer (CRC)

Authorization of 12 months may be granted for treatment of colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma.

C.    Small Bowel Adenocarcinoma

Authorization of 12 months may be granted for treatment of small bowel adenocarcinoma.

D.    Ampullary Adenocarcinoma

Authorization of 12 months may be granted for treatment of intestinal-type ampullary adenocarcinoma that is progressive, unresectable, or metastatic.

E.    Non-Small Cell Lung Cancer (NSCLC)

Authorization of 12 months may be granted for treatment of recurrent, unresectable, advanced, or metastatic non-squamous NSCLC.

F.    CNS Cancer

Authorization of 12 months may be granted for treatment of the following types of CNS cancer:

1.     Glioma (WHO Grade 1)

2.     Diffuse high grade gliomas

3.     Glioblastoma

4.     IDH mutant astrocytoma (WHO Grade 2, 3 or 4)

5.     Oligodendroglioma (WHO Grade 2 or 3)

6.     Intracranial and Spinal Ependymoma (excludes subependymoma)

7.     Medulloblastoma

8.     Primary Central Nervous System Lymphoma

9.     Meningiomas

10.  Limited and Extensive Brain Metastases

11.  Metastatic Spine Tumors

G.    Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer

Authorization of 12 months may be granted for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and malignant sex cord stromal tumors.

H.    Uterine Neoplasms/Endometrial Carcinoma

Authorization of 12 months may be granted for treatment of progressive, advanced, recurrent, or metastatic uterine neoplasms or endometrial carcinoma.

I.      Cervical/Vaginal Cancer

Authorization of 12 months may be granted for treatment of persistent, recurrent, or metastatic cervical or vaginal cancer.

J.     Breast Cancer

Authorization of 12 months may be granted for treatment of recurrent or metastatic breast cancer.

K.    Renal Cell Carcinoma

Authorization of 12 months may be granted for treatment of relapsed or stage IV renal cell carcinoma.

L.    Soft Tissue Sarcoma

1.     Authorization of 12 months may be granted for treatment of angiosarcoma, as single agent therapy.

2.     Authorization of 12 months may be granted for treatment of solitary fibrous tumor or hemangiopericytoma, in combination with temozolomide.

M.   Mesothelioma

1.     Authorization of 12 months may be granted for treatment of malignant pleural mesothelioma, malignant peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma when any of the following criteria are met:

a.     As first-line therapy for unresectable disease in combination with pemetrexed and either cisplatin or carboplatin, followed by single-agent maintenance bevacizumab

b.     As subsequent therapy in combination with pemetrexed and either cisplatin or carboplatin if immunotherapy was administered as first-line treatment

2.     Authorization of 12 months may be granted for treatment of malignant peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma when used in combination with atezolizumab as subsequent therapy.

N.    Vulvar Carcinoma

Authorization of 12 months may be granted for treatment of unresectable locally advanced, recurrent, or metastatic vulvar carcinoma, including squamous cell carcinoma and adenocarcinoma.

O.    Hepatocellular Carcinoma

Authorization of 12 months may be granted for treatment of unresectable or metastatic hepatocellular carcinoma, when the requested medication will be used as initial treatment in combination with atezolizumab.

       III.    CONTINUATION OF THERAPY  

A.    Ophthalmic Disorders

For ophthalmic disorders, authorization of 12 months may be granted for continued treatment of an indication outlined in Section II for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

B.    All Other Indications

For all other indications, authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

MEDICATION QUANTITY LIMITS

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION  

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1.     Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; September 2022.

2.     Alymsys [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2022.

4.     Zirabev [package insert]. New York, NY: Pfizer Inc.; May 2021.

5.     Vegzelma [package insert]. Incheon, Republic of Korea: Celltrion, Inc.; September 2022.

6.     The NCCN Drugs & Biologics Compendium® © 2022 National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org. Accessed November 15, 2022.

7.     Micromedex Solutions [database online]. Truven Health Analytics, Greenwood Village, CO. Available at: http://www.micromedexsolutions.com. Accessed February 14, 2023.

8.     Chan WM, Lai TY, Lui DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93(2):150-154.

9.     Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration. Eye. 2010;24:203-213.

10.  CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.

11.  Russo V, Barone A, Conte E, et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29:511-5.

12.  Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. Ophthalmology. 2010;117:1078-1086.

13.  Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol. 2008;18(2):263-269.

14.  Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632-637.

15.  Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.

16.  American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp.

17.  American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp.

18.  American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp. 

19.  VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy in primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017. May;124(5):619-633.

20.  AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed February 14, 2023.

21.  Yong M, Zhou M, Deng G. Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis. BMC Ophthalmol. 2015;15:82.

22.  Kim JH, Kim JW, Lee TG, Lew YJ. Treatment outcomes in eyes with polypoidal choroidal vasculopathy with poor baseline visual acuity. J Ocul Pharmacol Ther. 2015;31(4):241-247.

23.  Oishi A. The evidence for the treatment of polypoidal choroidal vasculopathy. Nippon Ganka Gakkai Zasshi. 2015;119(11):781-786.

24.  Chang YS, Kim JH, Kim KM, et al. Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther. 2016;32(4):219-224.

25.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed November 18, 2022.

26.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed November 18, 2022.

27.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed November 18, 2022.

28.  Lexicomp [database online]. Hudson, OH: Lexi-Comp, Inc.; https://online.lexi.com/lco/action/home [available with subscription]. Accessed February 14, 2023.

ORIGINAL EFFECTIVE DATE: 2/1/2005

MOST RECENT REVIEW DATE: 4/1/2024

ID_CHS

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.